ReviewMultiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration
Introduction
Multiple sclerosis is an immune mediated disease of the central nervous system (CNS). Chronic neuroinflammation and neurodegeneration are the pathomorphological hallmarks of the disease and give rise to a great variety of clinical symptoms, of which fatigue is one of the most frequent and disabling [1], [2], [3]. Due to the high variability of the clinical presentation, it has been proposed to consider fatigue as a complex symptom composed of the three main components
- ▪
Asthenia/daytime tiredness,
- ▪
Pathological exhaustibility and
- ▪
Worsening of symptoms due to stress [4].
From a pathogenetic point of view, a distinction can be drawn between primary and secondary fatigue [5]:
- •
Primary fatigue is caused by the MS-pathology itself. This includes fatigue which a) shows a correlative to the lesion localization and is triggered by loss in connectivity between cortical and subcortical structures, b) is caused by mediators and cytokines that are released within the scope of the immune-mediated inflammation, or c) is caused by neuroendocrine dysfunctions as a result of lesions in central regulatory regions as is depicted in Fig. 1.
- •
Fatigue that results from impaired motor function, coincident accompanying diseases, pain or side effects of drugs is attributed to secondary fatigue. Secondary fatigue is not an alternative diagnosis but may rather coexist with primary fatigue in the same patient.
The distinction between primary and secondary fatigue is important from a theoretical perspective and may help practitioners as a guidance for the diagnostic process and treatment. Nevertheless, it may almost be impossible to pinpoint the role of these components in an individual patient who exhibits both primary and secondary fatigue at the same time [5]. Furthermore, the relative importance of the different mechanisms underlying primary fatigue is largely unknown due to the fact that most studies have concentrated either on biomarkers and patterns of inflammation or on functional reorganization and adaptive changes in the CNS of affected patients. The aim of this work is to compile the existing knowledge on the contribution of the different components of the autoimmune process to fatigue in patients suffering from MS.
Section snippets
MS-fatigue as a prominent symptom of CNS autoimmunity
The prevalence of fatigue is already high when other first symptoms of MS manifest; it can increase up to 85% in the first year of the disease and reach up to 95% as the disease progresses [3], [6], [7]. Unlike other symptoms of MS such as paresis or paresthesia, the clinical assessment of fatigue is considerably more difficult, which has led to a high degree of inconsistency in the existing epidemiological and therapeutic studies [8], [9], [10].
Since fatigue is a purely subjective symptom, its
Immunopathology and pathomorphological changes in MS
The relation between “fatigue” and the CNS damage caused by MS is not as straight as it is for other symptoms like motor weakness or visual disturbances which we are able to explain by distinct, circumscript lesions. As will be outlined further, fatigue reflects rather a cumulative CNS damage that is acquired in the course of MS. Therefore, the increasing knowledge on the diverse and complex pathomorphology of MS and the mechanisms of the underlying immune responses has contributed
Pathomorphological damage patterns and fatigue in MS
The severity of MS fatigue does not correlate with the cumulative lesion load or imaging signs of the present disease activity seen in standard clinical MRI [31], [32], [33]. Instead of their mere existence, it is rather the localization of the lesions (mainly prefrontal, temporal and thalamic) that determines the development and manifestation type of MS fatigue [34]. Table 1 summarizes the findings of studies on the correlation between imaging signs of immune mediated CNS damage and fatigue in
Cytokines, inflammation and MS-fatigue
Fatigue symptoms that resemble those seen in MS occur during chronic infections, systemic autoimmune diseases or malignant tumors (for reviews see [57], [58], [59], [60]). The common factor of all those diseases is that they are accompanied by chronic inflammation which is reflected by a complex pattern of changes in biochemical and molecular biomarkers in blood and cerebrospinal fluid (recent reviews are given in [67], [68]). From basic and clinical experience it is known for a long time that
Neuroendocrine disorders in MS
Dysfunctions of the hypothalamus and corresponding vegetative–emotional changes are prevalent among MS patients. Since alterations of endocrine may interfere with immune functions, they may either be considered as a possible cause or a consequence of the immunological process of the disease [92].
On the basis of existing data, it can be assumed that in MS patients, dysfunctions in the regulation of the hypothalamus-pituitary adrenal-gland axis occur due to hypothalamic lesions [93], [94]. From a
Beyond central damage: secondary fatigue in MS patients
Besides the immunological disease process and its effects on the functioning of the CNS, fatigue may also be caused by numerous other factors such as adverse effects of medications, other MS-symptoms or diseases coinciding with MS which interfere with the patients' physical or mental strength and capacity. For example, many patients with bladder dysfunction suffer from a frequent urge to urinate at night. As a consequence, their sleep pattern is disturbed, which leads to increased daytime
Therapeutical implications
The stabilization of the progression of MS and the effective symptomatic management of existing impairments are central concerns of patient care. In particular, due to the fact that a significant increase in symptom-free or low-symptom life years can be achieved with a consistent immunomodulatory therapy, it is becoming more and more important to gain an accurate knowledge of the potential risks and benefits of the prescribed substances.
Immunotherapeutic treatment has the goal to slow or hold
Conclusion
Fatigue is a frequent and debilitating symptom of MS. As its clinical presentation is highly variable, it seems likely that the same applies to its pathophysiology. Diffuse cortical damage, circumscribed lesions and compensatory neuroplasticity can be seen in the CNS of all MS patients to different extents. Imaging studies have shown that immune mediated CNS and the development of fatigue are not linked by a simple correlation of lesion load and symptom severity. The lesion patterns that have
Abbreviations
- CMRGlu
Cerebral metabolic rate for glucose utilization
- CNS
Central Nervous Systems
- EMIF-SEP
Échelle Modifiée Impact de la Fatigue — Sclèrose en Plaques
- FDG-PET
18F-fluorodeoxyglucose positron emission tomography
- FSMC
Fatigue Scale for Motor and Cognitive Functions
- FSS
Fatigue Severity Scale
- HADS
Hospital Anxiety and Depression Scale
- HC
healthy controls
- IL
interleukin
- MFIS
modified Fatigue Impact Scale
- MS
Multiple sclerosis
- MS0
MS patients without fatigue
- MSF
MS patients with fatigue
- RA
rheumatoid arthritis
- RRMS
Conflicts of interest
The authors declare that they have no competing interest in connection with this paper.
Take-home messages
- •
Fatigue is frequent and debilitating with a highly variable clinical presentation.
- •
The pathophysiology of MS-fatigue is thus also variable and consists of a combination of:
- ○
Diffuse cortical damage, circumscribed lesions and compensatory neuroplasticity
- ○
Lesion clusters in distinct regions of frontal and parietotemporal lobes as well as thalamus and basal ganglia
- ○
- •
Chemical mediators of inflammation could not be proven unequivocally to be related to MS-fatigue.
- •
Modern immunotherapeutics lead to
References (155)
- et al.
Immune-mediated CNS diseases: a review on nosological classification and clinical features
Autoimmun Rev
(2012) - et al.
Symptomatology of MS: results from the German MS Registry
J Neurol
(2009) - et al.
Prevalence of fatigue in patients with multiple sclerosis and its effect on the quality of life
J Neurosci Rural Pract
(2013) - et al.
Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors
Mult Scler
(2000) - et al.
Origin of fatigue in multiple sclerosis: review of the literature
Neurorehabil Neural Repair
(2008) - et al.
Natural history of multiple sclerosis symptoms
Int J MS Care
(2013) - et al.
Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis
J Neurol Neurosurg Psychiatry
(2015) - et al.
A medical definition of fatigue in multiple sclerosis
QJM
(2008) Is there a cognitive signature for multiple sclerosis-related fatigue?
Mult Scler
(2015)- et al.
The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue
Mult Scler
(2009)
The impact of fatigue on patients with multiple sclerosis
Can J Neurol Sci
The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus
Arch Neurol
Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trondelag County, Norway
Mult Scler
The Hospital Anxiety and Depression Scale
Acta Psychiatr Scand
Advanced MRI unravels the nature of tissue alterations in early multiple sclerosis
Ann Clin Transl Neurol
Axonal loss in multiple sclerosis: causes and mechanisms
Handb Clin Neurol
Axonal damage in acute multiple sclerosis lesions
Brain
Imaging axonal damage of normal-appearing white matter in multiple sclerosis
Brain
Magnetic resonance imaging of grey matter damage in people with MS
Int MS J
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Brain
Bimonthly evolution of cortical atrophy in early relapsing–remitting multiple sclerosis over 2 years: a longitudinal study
Mult Scler Int
Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis
Mult Scler
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination
Ann Neurol
Histologie de la sclerose en plaques
Gaz Hop
Axonal transection in the lesions of multiple sclerosis
N Engl J Med
Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy
Brain Pathol
Multiple sclerosis: brain-infiltrating CD8 + T cells persist as clonal expansions in the cerebrospinal fluid and blood
Proc Natl Acad Sci U S A
Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics
Brain
Oxidative damage in multiple sclerosis lesions
Brain
Targets of the humoral autoimmune response in multiple sclerosis
Autoimmun Rev
A preliminary study of magnetization transfer and diffusion tensor MRI of multiple sclerosis patients with fatigue
J Neurol
Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability
J Neurol Sci
Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients
Neurology
Regional but not global brain damage contributes to fatigue in multiple sclerosis
Radiology
Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability
J Neurol Sci
Cortical thickness and surface area relate to specific symptoms in early relapsing–remitting multiple sclerosis
Mult Scler
Relationship of cortical atrophy to fatigue in patients with multiple sclerosis
Arch Neurol
Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis
Mult Scler
Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing–remitting multiple sclerosis
Mult Scler
Tract-specific white matter correlates of fatigue and cognitive impairment in benign multiple sclerosis
J Neurol Sci
Regional brain atrophy and functional connectivity changes related to fatigue in multiple sclerosis
PLoS One
Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways
Mult Scler
Frontal networks play a role in fatigue perception in multiple sclerosis
Behav Neurosci
Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis
Brain
Abnormal cervical cord function contributes to fatigue in multiple sclerosis
Mult Scler J
Association of a deficit of arousal with fatigue in multiple sclerosis: effect of modafinil
Neuropharmacology
Is there a cognitive signature for MS-related fatigue?
Mult Scler
Central motor drive is increased during voluntary muscle contractions in multiple sclerosis
Muscle Nerve
Corticospinal output during muscular fatigue differs in multiple sclerosis patients compared to healthy controls
Mult Scler
Functional MRI during the execution of a motor task in patients with multiple sclerosis and fatigue
Radiol Med
Cited by (104)
Roflumilast: Modulating neuroinflammation and improving motor function and depressive symptoms in multiple sclerosis
2024, Journal of Affective DisordersImmune-mediated cognition impairment in multiple sclerosis
2023, Translational Neuroimmunology: Multiple Sclerosis: Volume 8Network analysis characterizes key associations between subjective fatigue and specific depressive symptoms in early relapsing-remitting multiple sclerosis
2023, Multiple Sclerosis and Related DisordersCitation Excerpt :In pwMS, a number of mechanistic hypotheses have been proposed to explain the common co-occurrence of fatigue and depression, such as dysregulation of the hypothalamic‐pituitary‐adrenal axis (Feinstein et al., 2014). In addition, inflammation and cytokine production in response to underlying pathology of MS have been hypothesized to play a role in the experience of both fatigue (Patejdl et al., 2016) and depression (Feinstein et al., 2014) in pwMS, perhaps mediated by effects on brain structures implicated in reward processing (Palotai and Guttmann, 2020; Feinstein et al., 2014; Heitmann et al., 2020). This hypothesis is in accordance with the finding of a significant relationship between fatigue severity and anhedonia in our cohort.
Evaluation of the relationship between the morphometric structure of the pituitary gland and fatigue in patients with multiple sclerosis
2023, Multiple Sclerosis and Related DisordersThermoregulatory dynamics reveal sex-specific inflammatory responses to experimental autoimmune encephalomyelitis in mice: Implications for multiple sclerosis-induced fatigue in females
2022, Brain, Behavior, and Immunity - HealthCitation Excerpt :In turn, the higher female-to-male ratio reflected by inflammatory cytokine responses to EAE (Golden and Voskuhl, 2017; Hoghooghi et al., 2020) may also explain sex disparities in behavioural responses to disease pathogenesis. In humans, chronic fatigue syndrome (CFS) represents a common clinical sign of MS closely related to inflammation and changes in cytokines (Montoya et al., 2017; Ormstad et al., 2020; Patejdl et al., 2016), and it predominantly affects women (Faro et al., 2016). Excessive pro-inflammatory cytokine levels are causally associated with fever, fatigue, myalgias, sleep disturbances, and cognitive and mood disorders (Komaroff, 2017; Montoya et al., 2017) and they play a causal role in the onset of fatigue in MS (Ormstad et al., 2020).